Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease

Dimitrios C. Ladakis, Kimystian L. Harrison, Matthew D. Smith, Krista Solem, Sachin P. Gadani, Larissa Jank, Soonmyung Hwang, Farzaneh Farhadi, Blake E. Dewey, Kathryn C. Fitzgerald, Elias S. Sotirchos, Shiv Saidha, Peter A. Calabresi, Pavan Bhargava

This research paper, recently published as a preprint, explores the role of bile acid metabolism in Multiple Sclerosis (MS). The study combines an observational longitudinal cohort to establish bile acids as predictors of neurodegeneration with a Phase 1/2a randomized controlled trial to test the safety and biological activity of tauroursodeoxycholic acid (TUDCA) supplementation in patients with progressive MS.

TL;DR

Baseline levels of primary bile acids predict the rate of brain and retinal atrophy in MS patients, suggesting their potential as biomarkers for disease progression. A 16-week clinical trial demonstrated that oral TUDCA supplementation is safe, tolerable, and induces significant immunomodulatory shifts and gut microbiome changes that favor neuroprotection.

What Problem Does This Paper Address?

While many treatments exist for relapsing-remitting MS, options for Progressive MS (PMS) remain limited. PMS is characterized by steady neurodegeneration (atrophy) rather than acute inflammatory "flares." Researchers have noted that bile acid (BA) metabolism—a key component of the gut-liver-brain axis—is often dysregulated in MS patients.

The authors sought to bridge two gaps:

  1. Predictive Biomarkers: Can circulating BA levels at baseline predict how fast a patient’s brain or retina will atrophy over several years?
  2. Therapeutic Potential: Is supplementing with TUDCA (a secondary bile acid with known anti-inflammatory properties in animal models) safe for humans with PMS, and does it actually change their internal biology?

Methods

The study utilized a two-pronged approach:

  • Observational Cohort: The researchers analyzed global metabolomics from serum samples of MS patients. They then correlated these baseline "chemical signatures" with longitudinal imaging data (serial brain MRIs and retinal Optical Coherence Tomography [OCT]) using linear mixed-effects models and Metabolite Set Enrichment Analysis (MSEA).
  • Clinical Trial: A double-blind, placebo-controlled, phase 1/2a trial was conducted at Johns Hopkins University. 54 participants with PMS were randomized (1:1) to receive either 2g of oral TUDCA daily or a placebo for 16 weeks. The team monitored safety (adverse events), targeted metabolomics (15 specific BAs), immunophenotyping (via flow cytometry), and gut microbiome composition (via shotgun metagenomics).

Datasets

  • MRI Cohort: 107 patients with MS followed with annual scans.
  • OCT Cohort: 192 patients with MS followed with semi-annual scans.
  • Clinical Trial Cohort: 54 randomized participants (26 placebo, 28 TUDCA); 47 completed enough visits for the final analysis.
  • Reference Data: The study utilized standard biological classifications from Metabolon for metabolite grouping and the MetaPhlAn/HUMAnN pipelines for microbiome analysis.

Key Insights and Ideas

  • Primary vs. Secondary BAs: A fascinating dichotomy emerged. Higher levels of primary bile acids (synthesized in the liver) were associated with slower atrophy of the brain and retina. Conversely, higher levels of secondary bile acids (modified by gut bacteria) were linked to faster accumulation of T2 lesions in the brain.
  • The "Deep" Retina Connection: In PMS, the outer nuclear layer (ONL) of the retina atrophies faster than in other MS types. This study found that primary BA levels specifically predicted ONL thinning, providing a potential window into deep-tissue neurodegeneration.
  • Immunological Shift: TUDCA didn't just increase bile acid levels; it appeared to "re-program" the immune system. It decreased pro-inflammatory T-cell subsets (Th1 and Th1/17) and increased "naive" CD4+ T-cells, suggesting a shift away from a chronic inflammatory state.
  • Microbiome & NAD+: TUDCA supplementation increased the abundance of Bifidobacterium adolescentis (a GABA producer) and upregulated the NAD salvage pathway in the gut. Since NAD+ is critical for mitochondrial health and energy production, this suggests a gut-mediated mechanism for neuroprotection.

Key Results

  • Imaging Associations: Higher primary BA levels predicted slower whole-brain atrophy (NES=1.7, p=0.01) and slower ONL atrophy (p=0.002).
  • Safety: TUDCA was safe and well-tolerated. There was no significant difference in total adverse events (AEs) between groups (33% placebo vs. 38% TUDCA, p=0.77). Gastrointestinal side effects (like diarrhea) were more frequent in the TUDCA group but generally mild.
  • Metabolic Impact: TUDCA treatment significantly increased serum levels of TUDCA (beta=2.52, p<0.001) and its derivatives, confirming successful absorption and metabolic processing.
  • Clinical Outcomes: No significant changes were seen in clinical disability scores (EDSS, MSFC) or fluid biomarkers (NfL, GFAP). This was expected given the short 16-week duration of the trial.

Limitations and Future Work

The authors acknowledge several constraints:

  • Trial Duration: 16 weeks is insufficient to observe changes in clinical disability or structural brain atrophy, which typically require 1-2 years to manifest.
  • Sample Size: While adequate for a Phase 1/2a safety study, the cohort was too small to definitively prove clinical efficacy.
  • Observational Nature: The retrospective nature of the imaging cohort means the predictive power of BAs needs validation in prospective, independent groups.

Future Work: The biological "signals" found in the immune system and microbiome provide a strong rationale for a larger, multi-year Phase 2/3 trial to determine if TUDCA can actually slow the progression of disability in MS.

Summary updated

Abstract

Bile acid metabolism in MS is linked with brain and retinal atrophy. TUDCA supplementation in PMS is safe, tolerable and has measurable biological effects that warrant further evaluation in larger trials with a longer treatment duration.
BibTeX
@inproceedings{ladakis2024bile,
  author = {Dimitrios C. Ladakis and Kimystian L. Harrison and Matthew D. Smith and Krista Solem and Sachin P. Gadani and Larissa Jank and Soonmyung Hwang and Farzaneh Farhadi and Blake E. Dewey and Kathryn C. Fitzgerald and Elias S. Sotirchos and Shiv Saidha and Peter A. Calabresi and Pavan Bhargava},
  title = {{Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease}},
  booktitle = {Med},
  year = {2024},
  doi = {10.1016/j.medj.2024.09.011},
}
Figure